KR20160013046A - Ｐｃｓｋ9 기능획득 돌연변이에서 기인한 상염색체 우성 고콜레스테롤혈증의 치료법 - Google Patents

Ｐｃｓｋ9 기능획득 돌연변이에서 기인한 상염색체 우성 고콜레스테롤혈증의 치료법 Download PDF

Info

Publication number
KR20160013046A
KR20160013046A KR1020157033966A KR20157033966A KR20160013046A KR 20160013046 A KR20160013046 A KR 20160013046A KR 1020157033966 A KR1020157033966 A KR 1020157033966A KR 20157033966 A KR20157033966 A KR 20157033966A KR 20160013046 A KR20160013046 A KR 20160013046A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157033966A
Other languages
English (en)
Korean (ko)
Inventor
게리 스워골드
스코트 멜리스
윌리엄 제이. 새시엘라
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20160013046A publication Critical patent/KR20160013046A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C07K2316/96—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Mycology (AREA)
KR1020157033966A 2013-05-30 2014-05-29 Ｐｃｓｋ9 기능획득 돌연변이에서 기인한 상염색체 우성 고콜레스테롤혈증의 치료법 Ceased KR20160013046A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361828730P 2013-05-30 2013-05-30
US61/828,730 2013-05-30
US201361889553P 2013-10-11 2013-10-11
US61/889,553 2013-10-11
US201361901212P 2013-11-07 2013-11-07
US61/901,212 2013-11-07
PCT/US2014/040050 WO2014194111A1 (en) 2013-05-30 2014-05-29 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations

Publications (1)

Publication Number Publication Date
KR20160013046A true KR20160013046A (ko) 2016-02-03

Family

ID=51205567

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157033966A Ceased KR20160013046A (ko) 2013-05-30 2014-05-29 Ｐｃｓｋ9 기능획득 돌연변이에서 기인한 상염색체 우성 고콜레스테롤혈증의 치료법

Country Status (12)

Country Link
US (2) US20140356370A1 (enExample)
EP (1) EP3004172B1 (enExample)
JP (1) JP6423868B2 (enExample)
KR (1) KR20160013046A (enExample)
CN (2) CN105263963B (enExample)
AU (1) AU2014274077B2 (enExample)
CA (1) CA2912101A1 (enExample)
EA (1) EA201592304A1 (enExample)
IL (1) IL242251B (enExample)
TW (1) TWI682780B (enExample)
WO (1) WO2014194111A1 (enExample)
ZA (1) ZA201507798B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SI2668212T1 (en) 2011-01-28 2018-08-31 Sanofi Biotechnology, Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CN105705521A (zh) 2013-06-07 2016-06-22 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
MX373298B (es) * 2013-10-11 2020-05-20 Sanofi Biotechnology Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN107206068A (zh) 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016100615A2 (en) * 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Anti-pd-l1 antibodies
CA3031742A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
CN109923411B (zh) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3609532A1 (en) 2017-04-13 2020-02-19 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
CN110431153B (zh) * 2017-06-30 2023-09-19 苏州盛迪亚生物医药有限公司 一种pcsk-9抗体药物组合物及其用途
MX2020002850A (es) 2017-09-19 2020-07-24 Regeneron Pharma Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
AU2018385394B2 (en) 2017-12-13 2024-05-02 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CA3125765A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
IL323016A (en) * 2019-11-18 2025-10-01 Ad Pharmaceuticals Co Ltd Anti-pcsk9 antibody and its use
EP4072672A1 (en) * 2019-12-10 2022-10-19 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
EP4204563A1 (en) 2020-08-25 2023-07-05 Regeneron Pharmaceuticals, Inc. Treatment of sepsis with pcsk9 and ldlr modulators
CN116189765B (zh) * 2023-02-23 2023-08-15 上海捷易生物科技有限公司 一种iPS细胞遗传学风险评估系统及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012308797B2 (en) * 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)

Also Published As

Publication number Publication date
HK1216896A1 (en) 2016-12-09
TWI682780B (zh) 2020-01-21
JP2016522211A (ja) 2016-07-28
AU2014274077B2 (en) 2019-09-26
US20140356370A1 (en) 2014-12-04
CA2912101A1 (en) 2014-12-04
JP6423868B2 (ja) 2018-11-14
US20190330371A1 (en) 2019-10-31
CN105263963B (zh) 2021-03-05
AU2014274077A1 (en) 2015-11-19
EP3004172A1 (en) 2016-04-13
IL242251B (en) 2020-02-27
EA201592304A1 (ru) 2016-04-29
WO2014194111A1 (en) 2014-12-04
CN113144195A (zh) 2021-07-23
CN105263963A (zh) 2016-01-20
TW201536315A (zh) 2015-10-01
ZA201507798B (en) 2017-04-26
EP3004172B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
KR101964031B1 (ko) 전구단백질 전환효소 서브틸리신 켁신-9 (ＰＣＳＫ9)의 억제제를 투여함으로써 지질단백질(ａ)의 농도를 낮추는 방법
KR20160013046A (ko) Ｐｃｓｋ9 기능획득 돌연변이에서 기인한 상염색체 우성 고콜레스테롤혈증의 치료법
KR101699707B1 (ko) Ｐｃｓｋ9에 대한 고친화성 사람 항체
RU2721279C2 (ru) Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
CN113354732B (zh) 针对埃博拉病毒糖蛋白的人抗体
AU2013302925B2 (en) Anti-PCSK9 antibodies with pH-dependent binding characteristics
CN110240651B (zh) 针对fel d1的人源抗体及其使用方法
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
KR20160013047A (ko) 전단백질 전환효소 서브틸리신 켁신-9 (ｐｃｓｋ9)의 억제제를 투여함으로써 잔여 콜레스테롤 및 지단백 분획을 낮추는 방법
KR101842570B1 (ko) 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체
DK2809681T3 (en) ANTI-ASIC1 antibodies and uses thereof
KR20180038020A (ko) 항-angptl８ 항체 및 이의 용도
KR20240128136A (ko) Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
KR20140037218A (ko) 항-ａｎｇｐｔｌ３ 항체 및 이의 용도
KR20190078650A (ko) 항-angptl8 항체를 사용하는 비만의 치료 방법
KR20190075133A (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
KR20200128125A (ko) 신체 조성을 변경하기 위한 방법
KR20150084007A (ko) 항-프로키네티신 수용체 (ｐｒｏｋｒ) 항체 및 이의 용도
HK1216896B (en) Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
TW201242615A (en) Human antibodies to PCSK9 for use in methods of treatment based on particular dosage regimens

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190528

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201022

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210426

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201022

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I